Where can I find the primary clinical evidence?

Primary trials are published in peer-reviewed journals (NEJM, JAMA, Lancet) with PubMed PMIDs cited throughout GLP-1 Editorial.

Editorial Disclosure: GLP-1 Editorial is an editorial publication operated by Ranika Editorial Group LLC. We do not provide medical care, prescribe medication, manufacture or compound medication, or sell GLP-1 treatment. Our rankings are based on our published v3.0 transparency rubric, publicly available provider information, cited sources, and periodic review updates. If a provider relationship, sponsorship, affiliate relationship, or material connection exists, it is disclosed on the relevant page and at /affiliate-disclosure.html.

Clinical Reference · Updated 2026-05-08

Mechanism of Action

Semaglutide selectively activates the GLP-1 receptor: glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying, reduced caloric intake. Half-life ~7 days.

Clinical referenceUpdated 2026-05-08

Editorial team

Dr. Sam Saberian · Lead Medical Researcher

Medical review by Alen A. Schwartz, MD · Edited by Julliana Edwards · Last updated 2026-05-11

Overview

Semaglutide selectively activates the GLP-1 receptor: glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying, reduced caloric intake. Half-life ~7 days.

Related clinical pages

Important medical and regulatory disclosure: Compounded semaglutide and compounded tirzepatide are not FDA-approved. They are not the same as Ozempic, Wegovy, Mounjaro, or Zepbound. Compounded medications may be prescribed only when clinically appropriate after review by a licensed medical provider. GLP-1 Editorial does not provide medical advice, prescribe medication, manufacture medication, or operate a pharmacy.